Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform

On November 18, 2026 Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, reported that the company licensed the PACK-IT technology enabling in vivo engineering of KIR-CAR T cells from Stanford Medicine. The new licensing agreement provides Verismo with breakthrough technology from the lab of Crystal Mackall, MD, Ernest and Amelia Gallo Family Professor and professor of pediatrics and medicine at Stanford Medicine and founding director of the Stanford Center for Cancer Cell Therapy. The agreement will allow Verismo to extend its multi-chain KIR-CAR platform into next-generation in vivo delivery of KIR-CAR T cell therapies, with the potential to reduce time-to-treatment and cost and broaden patient access over time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Verismo’s multi-chain KIR-CAR platform is designed to take CAR T therapy beyond the single-chain limitations of current approaches, with the potential to deliver durable anti-tumor responses while minimizing off-target toxicity. The platform is currently advancing in two Phase 1 clinical trials — SynKIR-110 (NCT05568680) in solid tumors and SynKIR-310 (NCT06544265) in B-cell malignancies. Both trials have generated early positive signals presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2026 Annual Meeting: initial STAR-101 data for SynKIR-110 showed a positive safety profile with dose-dependent efficacy signals and no dose-limiting toxicities; initial CELESTIAL-301 data for SynKIR-310 included a complete response in a follicular lymphoma patient at the lowest dose level, sustained beyond six months.

"Our KIR-CAR platform is at the center of everything Verismo is building — designed to take CAR T beyond its current limitations by delivering a durable anti-tumor response while minimizing off-target toxicity," said Bryan Kim, CEO and Co-Founder of Verismo Therapeutics. "Today, KIR-CAR is advancing along the established CAR T pathway in two Phase 1 clinical trials, and adding the PACK-IT technology is intended to extend the platform into next-generation, off-the-shelf in vivo delivery — realizing the full potential of KIR-CAR to reach more patients, faster, and at lower cost."

Approved CAR T therapies are engineered using ex vivo manufacturing — a personalized approach in which each patient’s cells are collected, engineered, expanded, and quality-tested in a facility over a period of weeks before being returned to the patient. This lengthy, well-characterized process has enabled the current generation of approved CAR T therapies, but its complexity can limit patient access and increase cost.

By contrast, the licensed Programmable Antigen-Mediated Cellular Knock-in of T cell (PACK-IT) platform is a versatile CAR T engineering technology that uses engineered T cell-targeted lentiviral particles to deliver CAR genes directly to T cells, and can be deployed either in vivo, to reprogram a patient’s own T cells in the body, or ex vivo, in an accelerated ex vivo workflow. In preclinical data published at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2025 Annual Meeting, PACK-IT generated CAR T cells with superior potency compared to conventional lentivirus, and enabled in vivo generation of CD19-CAR T cells capable of controlling leukemia in preclinical models.¹ Verismo intends to apply PACK-IT primarily in an off-the-shelf, in vivo configuration — compressing the multi-week ex vivo manufacturing workflow into a same-day in vivo step with the potential to lower cost, shorten time to treatment, and improve patient access over time.

About the KIR-CAR Platform

The KIR-CAR platform is a multi-chain T cell therapy that has shown highly effective solid tumor treatment in otherwise CAR-resistant animal models with hard-to-treat tumors. Using NK cell-derived killer immunoglobulin-like receptor (KIR) and DAP12 to split the target binding and T cell activation signals provides a novel paired immune-receptor activation that is independent from CD3 signaling and works independently of co-stimulation. KIR-CAR enables sustained cell receptor expression in T cells, and induces deeper, more durable tumor treatments. Together, this multi-chain cell signaling platform provides the potential to deliver effective patient treatments by eliminating the constant background activation and early T cell exhaustion observed in conventional single-chain CAR T therapy, with potential to treat patients with both solid and hematologic tumors.

(Press release, Verismo Therapeutics, NOV 18, 2026, View Source [SID1234674926])

Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026

On November 18, 2026 Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be featured in approximately 100 abstracts, including 27 oral presentations, at the 68th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), taking place Dec. 12–15, 2026, in New Orleans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research at this year’s meeting reflects the continued evolution of MRD assessment across hematologic malignancies, moving beyond measuring the depth of treatment response to informing how therapies are developed, evaluated, and adapted based on individual patient response. Across 20 unique biopharma-sponsored studies featuring clonoSEQ, MRD is utilized as a primary endpoint in four studies and a secondary endpoint in 11, underscoring how highly sensitive MRD assessment has become integral to evaluating therapeutic efficacy and advancing new treatment approaches.

Key highlights include:

Advancing MRD-informed treatment strategies in multiple myeloma: At ASH (Free ASH Whitepaper), data from pivotal Phase 3 studies, including PERSEUS, AURIGA, and BENEFIT, reinforce clonoSEQ’s established role in evaluating treatment response, while research from PERSEUS and IMMUNOPLANT highlights its use in informing treatment strategies, including maintenance de-escalation and consolidation therapy. Additionally, real-world research from the Icahn School of Medicine at Mount Sinai leveraging clonoSEQ data identifies patients with sustained MRD negativity and survival comparable to the general population, highlighting the ability to inform treatment discontinuation and providing new evidence supporting the possibility of cure in multiple myeloma.
Evaluating MRD-guided treatment in chronic lymphocytic leukemia (CLL): Several studies, including the Phase 3 MAJIC study, demonstrate the use of clonoSEQ in guiding the duration of therapy and assessing response. In addition, in the MIRACLE study, MRD is also used as a primary endpoint.
Strengthening MRD testing utility relative to PET/CT in lymphoma: New real-world data from Adaptive, Hackensack University Medical Center, and the University of Nebraska Medical Center, as well as study data from Wilmot Cancer Center, show the prognostic value of clonoSEQ MRD assessment following frontline treatment in diffuse large B-cell lymphoma (DLBCL), including its ability to complement imaging.

"The research being presented at ASH (Free ASH Whitepaper) underscores clonoSEQ’s established position in pivotal clinical trials and showcases its ever-expanding role as a tool to inform patient care strategies across blood cancers," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. "Multiple myeloma offers a powerful example of this progress, with updated clinical guidelines, a new definition of cure, and important Phase 3 research reinforcing the value of systematic MRD assessment. With a strong foundation of clinical evidence, regulatory validation and unparalleled real-world patient experience, Adaptive is helping shape the future of MRD-guided care for blood cancer patients."

A list of selected abstracts featuring clonoSEQ is available here.

About clonoSEQ
clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell acute lymphoblastic leukemia (T-ALL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.

clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.

clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

(Press release, Adaptive Biotechnologies, NOV 18, 2026, View Source [SID1234674942])

Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer

On November 18, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported compelling preclinical data that supports expanding the clinical development of atebimetinib, its investigational deep cyclic MEK inhibitor, to a third tumor type: anaplastic thyroid cancer (ATC). The findings were presented at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The preclinical data demonstrate broad anti-tumor activity for atebimetinib across genetically diverse ATC models, enhanced chemotherapy potency in vitro, and superior tumor control with atebimetinib plus chemotherapy compared with chemotherapy or standard targeted therapy alone in an animal model of ATC.

These findings provide important scientific support for Immuneering’s recently announced Phase 2 clinical program evaluating atebimetinib in patients with ATC, an aggressive malignancy with limited treatment options and a five-year survival rate of less than 10%.

"We are very excited to expand the development of atebimetinib to a third tumor type, for patients with anaplastic thyroid cancer," said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering Corporation. "In first-line pancreatic cancer patients, we reported compelling data at ASCO (Free ASCO Whitepaper) for atebimetinib+chemo, including long survival and an excellent tolerability profile in an all-comers population, and are excited to share another update on that trial in 1H 2027. Enthusiasm is high for our Phase 3 MAPKeeper 301 trial of atebimetinib+chemo in first line pancreatic cancer patients, which is enrolling ahead of schedule, and we are preparing to dose the first patient in our Phase 2 study of atebimetinib+anti-PD-1 in first-line RAS mutant lung cancer by the end of the year. This incredible momentum gives us the opportunity to serve more patients, and the preclinical data we reported makes it clear that running a Phase 2 study of atebimetinib+chemotherapy in anaplastic thyroid cancer is an important next step for atebimetinib. We observed activity across a broad range of ATC models, including those with different underlying genetic drivers, and importantly, we saw that adding atebimetinib to chemotherapy produced substantially greater tumor control than either chemotherapy or established targeted therapy alone in our preclinical model, including following progression on targeted therapy. These results reinforce our confidence in the scientific rationale for the Phase 2 ATC program we announced last week and underscore the potential of atebimetinib to help a broad and expanding set of cancer patients."

Broad anti-tumor activity across genetically diverse ATC models

Atebimetinib demonstrated dose-dependent inhibition of tumor cell proliferation across all nine ATC cell lines evaluated, including models harboring BRAF V600E mutations, RAS mutations and no identified MAPK pathway alteration.
Six of the nine ATC cell lines demonstrated sensitivity to atebimetinib at concentrations below the free-drug maximum plasma concentrations achieved in patients at clinically evaluated doses.
These findings suggest that atebimetinib’s potential utility in ATC may extend beyond patients with BRAF V600E mutations, who currently have access to targeted BRAF/MEK inhibitor therapy.

Enhanced chemotherapy potency across multiple treatment combinations

The addition of atebimetinib increased the potency of three chemotherapy agents commonly used in ATC – pemetrexed, carboplatin and paclitaxel – reducing the concentrations required to inhibit tumor cell proliferation in most ATC cell lines evaluated.
These findings are consistent with the proposed mechanism of atebimetinib, which is designed to deliver deep cyclic inhibition of MEK signaling, potentially limiting the adaptive MAPK pathway reactivation that can enable tumor cells to survive chemotherapy.
Superior tumor control in an ATC animal model, including following targeted therapy

In an ongoing BRAF V600E-mutant ATC xenograft study, atebimetinib combined with carboplatin and pemetrexed demonstrated superior tumor control compared with chemotherapy alone or the targeted therapy combination of dabrafenib and trametinib.
Importantly, the atebimetinib combination also demonstrated tumor control when administered following prior treatment with dabrafenib and trametinib, supporting its potential utility in patients whose disease has progressed following targeted therapy.
All treatment regimens evaluated in the study were reported to be well tolerated. The study remains ongoing, with additional treatment groups and durability data expected.

Addressing a Significant Unmet Medical Need in ATC

Anaplastic thyroid cancer is one of the most aggressive and lethal solid tumors, with a five-year survival rate of less than 10%. Despite advances in targeted therapy for patients with BRAF V600E-mutant disease, treatment options remain limited, particularly following disease progression and for patients without this mutation.

Analysis of genomic data from 379 patients with ATC in AACR (Free AACR Whitepaper) Project GENIE found that approximately 78% had an alteration involving the MAPK signaling pathway, highlighting the importance of this pathway in ATC biology.

Atebimetinib’s deep cyclic MEK inhibition is designed to disrupt oncogenic MAPK signaling while allowing recovery of normal cells between doses. Immuneering believes this differentiated approach may enable atebimetinib to enhance the anti-tumor effects of chemotherapy while potentially overcoming limitations associated with conventional chronic MEK inhibition.

The preclinical findings presented today support Immuneering’s planned Phase 2 clinical trial of atebimetinib plus chemotherapy in second-line ATC, including patients with BRAF V600E-mutant disease previously treated with targeted therapy and patients with non-V600E disease.

Poster Presentation Details:
Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC).
Abstract Number: 144
Poster Number: PB-144
Presenter: Praveen Nair
Date: Wednesday, November 18, 2026

The poster is available on the publications section of Immuneering’s website.

About Atebimetinib

Atebimetinib is the first in a new category of oral drug candidates, Deep Cyclic Inhibitors (DCIs), designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Each of these mechanisms has been well established to improve survival in published studies. DCIs challenge the conventional model of sustained or continuous inhibition in oncology. Whereas most therapies are designed for sustained inhibition, driving cancer to adapt and develop resistance so tumors shrink quickly but temporarily, DCIs are designed to pulse faster than tumors can adapt, so tumors shrink slowly but durably. Moreover, DCIs aim to restore full transient signaling to healthy cells, with the goal of leading to fewer adverse events. Atebimetinib targets MEK, a key control point in the MAPK pathway (RAS-RAF-MEK-ERK), which is pathologically activated in a majority of cancers, including approximately 97% of pancreatic cancers. Targeting MEK blocks a broader range of MAPK pathway alterations because it is further downstream, creating the potential for more durable benefit.

(Press release, Immuneering, NOV 18, 2026, View Source [SID1234674911])

Racura Oncology Receives First Site Approval for Seamless Phase 2b/3 EMILI Trial of RC220 in Relapsed or Refractory Acute Myeloid Leukemia

On November 18, 2026 Racura Oncology Limited (ASX: RAC), a clinical-stage biopharmaceutical company, reported that Sheba Medical Center in Israel has granted ethics approval for the seamless Phase 2b/3 EMILI trial of RC220 in adults with relapsed or refractory acute myeloid leukemia (R/R AML). RC220 is Racura’s proprietary peripheral-intravenous formulation of the small-molecule anticancer agent (E,E)-bisantrene. Racura’s Board has approved trial initiation, with the Phase 2b stage funded from existing cash. Site activation at Sheba is expected by the end of 2026 with first patient dosing expected in Q1 2027. Additional sites in the United States, Europe and Australia are planned to be opened in 2027, subject to regulatory approvals and feasibility.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approval by Sheba’s Institutional Helsinki Committee is subject to minor patient consent-form updates that do not affect the trial design or endpoints. The Israeli Ministry of Health has confirmed that separate approval is not required, given prior clinical experience with bisantrene at Sheba. Site activation remains subject to institutional governance review, which is well advanced.

For patients with R/R AML, an aggressive cancer of the blood and bone marrow, the main curative option is an allogeneic hematopoietic stem cell transplant (allo-HSCT), which generally requires the leukemia to be brought into remission first. EMILI will test whether a single seven-day course of RC220 can induce remission so that patients can proceed to allo-HSCT, with exploratory analyses assessing whether RC220 suppresses MYC in patients’ leukemic cells. MYC protein is overexpressed in around 90% of patients with newly diagnosed AML, where higher levels correlate with shorter remissions and poorer survival (Ohanian et al., Leuk Lymphoma 2019; n = 265). The MYC protein has proven difficult to drug, and no direct MYC inhibitor has been approved. In preclinical cell and animal models, RC220 and (E,E)-bisantrene were found to inhibit MYC expression by binding to G-quadruplex structures in the MYC gene promoter.

Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said: "Ethics approval at Sheba Medical Center is an important step toward starting EMILI, our seamless Phase 2b/3 trial of RC220 in relapsed or refractory AML. EMILI will open first at Sheba, where Professor Arnon Nagler and his team have studied bisantrene in AML patients for many years. With this approval, our focus now turns to activating Sheba and our other sites, with the aim of generating the data needed to select the right RC220 dose for Phase 3."

EMILI Trial Design

EMILI (Evaluation of a MYC-silencing Intervention in Acute Myeloid LeukemIa) is a multicenter, adaptive, seamless Phase 2b/3 trial of RC220 monotherapy as salvage induction in adults aged 18 to 78 years with R/R AML who have received no more than three prior treatment regimens and are allo-HSCT candidates. RC220 is given as a 2-hour intravenous infusion daily on Days 1 to 7 of a single treatment cycle (Figure 1).

Phase 2b begins with a six-patient lead-in cohort at 175 mg/m2. Following Safety Review Committee (SRC) review, up to 62 additional patients will be randomized 1:1 (up to 31 per arm) to either 175 and 200 mg/m2 or 200 and 250 mg/m2, depending on the lead-in rate of complete remission (CR) or CR with incomplete hematologic recovery (CRi). In line with the US Food and Drug Administration’s (FDA) Project Optimus initiative, the recommended Phase 3 dose (RP3D) will be selected on CR/CRi rate, allo-HSCT eligibility, safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers.

Interim analyses after 11, 16 and 21 patients per arm allow Phase 2b to end early. Racura expects Phase 2b to take 18 to 24 months, depending on recruitment, site activation and the number of patients needed to identify the optimal dose.

Progression to the Phase 3 stage is subject to Phase 2b results, additional funding and an End-of-Phase 2 meeting with regulators. Under the same protocol, Phase 3 is designed to randomize patients 1:1 to RC220 at the RP3D or standard-of-care therapy, with the Phase 2b patients treated at the RP3D included in the Phase 3 RC220 analysis. The proposed primary endpoint is a composite of CR/CRi and allo-HSCT eligibility. Sample size, comparator and statistical design will be finalized after regulatory consultation.

Clinical and Scientific Rationale

RC110, an earlier formulation of (E,E)-bisantrene, was evaluated in two Sheba studies led by Professor Arnon Nagler, the EMILI Principal Investigator. In 10 patients with R/R AML who had received a median of three prior lines of therapy, RC110 monotherapy at 250 mg/m2, given on the same seven-day, daily 2-hour infusion schedule as EMILI, produced four clinically meaningful responses (40%; one complete and three partial remissions; Canaani et al., Eur J Haematol 2021). Combined with fludarabine and clofarabine in 21 treated patients, RC110 produced clinically meaningful responses in 6 of 15 evaluable patients (40% of evaluable), including five complete remissions with six patients proceeding to allo-HSCT within one to three months (Danylesko et al., Br J Haematol 2025). Together with the 1988 approval of an earlier bisantrene formulation for AML in France, these small, single-center, non-randomized studies informed the bridge-to-transplant design of EMILI, but do not predict its outcome. Unlike RC110, which required a central line, RC220 is formulated for peripheral-vein infusion and showed drug exposure equivalent to RC110 in a nonclinical GLP bridging study reported on 17 November 2026.

In a collaborative preclinical study by the University of Newcastle and Racura, (E,E)-bisantrene reduced MYC gene and protein levels at nanomolar concentrations in most AML cell lines tested and prolonged survival in mouse models of AML, including a patient-derived xenograft model (Murray et al., bioRxiv 2026; preprint, not yet peer reviewed). Because leukemic cells circulate in the blood, exploratory biomarker analyses in EMILI can measure MYC protein and MYC-regulated gene expression in serial blood samples, avoiding the repeated biopsies required in solid tumors, and compare these changes with clinical outcomes. While MYC effects can be measured from the first patient, Racura expects 12 to 18 patients will be needed to determine whether RC220 suppresses MYC in patients. These findings could also inform the use of RC220 in the HARNESS lung cancer and CPACS solid tumor trials, where MYC plays an important role in cancer cell proliferation and treatment resistance and where serial tumor sampling is less practical.

Upcoming Milestones

Next steps include appointing a contract research organization, registering the trial on ClinicalTrials.gov, obtaining FDA clearance and European regulatory approval through the European Medicines Agency’s Clinical Trials Information System, and activating additional sites. All timelines are estimates and subject to change.

About RC220

RC220 is Racura’s proprietary peripheral-intravenous formulation of (E,E)-bisantrene, a small-molecule anticancer agent that binds G-quadruplex DNA and RNA structures and inhibits MYC gene expression in preclinical models. RC220 has received FDA Orphan Drug Designation for AML, which provides eligibility for seven years of US market exclusivity upon approval, and Racura has filed composition-of-matter patent applications that, if granted, could provide up to 20 years of protection for (E,E)-bisantrene.

(Press release, Racura Oncology, NOV 18, 2026, View Source [SID1234674927])

Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer

On November 18, 2026 Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, reported that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027.

The engagement follows the U.S. Food and Drug Administration’s clearance of Telomir’s Investigational New Drug (IND) application and represents an important operational milestone as the Company advances toward clinical execution.

"Following FDA clearance of our IND, our priority has been to establish the clinical infrastructure necessary to advance Telomir-Zn into patients," said Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals. "We selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development. With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer."

"We are pleased to partner with Telomir Pharmaceuticals as it prepares to evaluate Telomir-Zn in patients with triple-negative breast cancer," said Clareece West, President at Linical. "Our CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping Telomir advance their important clinical program."

(Press release, Telomir Pharmaceutical, NOV 18, 2026, View Source [SID1234674943])